226922-93-6

Basic information

• Product Name: 6-fluoro-2,2-dimethyl-3,4-dihydro-2H-chromen-4-amine
• Synonyms: 2H-1-benzopyran-4-amine, 6-fluoro-3,4-dihydro-2,2-dimethyl-; 6-Fluoro-2,2-dimethylchroman-4-amine
• CAS NO: 226922-93-6
• Molecular Formula: C₁₁H₁₄FNO
• Molecular Weight: 195.2334
• Mol File: 226922-93-6.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 244.1°C at 760 mmHg
• Flash Point: 101.4°C
• Density: 1.099g/cm³
• Vapor Pressure: 0.031mmHg at 25°C
• Refractive Index: 1.507
• CAS DataBase Reference: 6-fluoro-2,2-dimethyl-3,4-dihydro-2H-chromen-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-fluoro-2,2-dimethyl-3,4-dihydro-2H-chromen-4-amine(226922-93-6)
• EPA Substance Registry System: 6-fluoro-2,2-dimethyl-3,4-dihydro-2H-chromen-4-amine(226922-93-6)

Safety Data

• Hazardous Substances Data: 226922-93-6(Hazardous Substances Data)

Usage

Chemical compound

6-fluoro-2,2-dimethyl-3,4-dihydro-2H-chromen-4-amine

Class

Amine

Derivative of

Chromene

Substituents

Fluorine at 6 position, dimethyl amino group at 4 position

Potential applications

Pharmacological and therapeutic

Research needed

Further studies required to understand properties, uses, and effects

Upstream product

• 132686-72-7 6-fluoro-2,2-dimethyl-chroman-4-ol 
• 105799-73-3 6-fluoro-2,2-dimethyl-chroman-4-one 
• 394-32-1 1-(5-fluoro-2-hydroxyphenyl)ethan-1-one 
• 405-51-6 4-fluorophenyl acetate 
• 371-41-5 4-Fluorophenol 
• 226922-88-9 4-(N-acetylamino)-3,4-dihydro-2,2-dimethyl-6-fluoro-2H-1-benzopyran 

Downstream Products

• 1040136-76-2 C₁₈H₁₉FN₂OS 

Relevant articles and documents

4,6-Disubstituted 2,2-dimethylchromans structurally related to the K ATP channel opener cromakalim: Design, synthesis, and effect on insulin release and vascular tone

Five series (ureas, thioureas, carbamates, sulfonylureas, and amides) of 4,6-disubstituted-2,2-dimethylchromans structurally related to cromakalim were prepared and evaluated, as putative ATP-sensitive potassium channel activators, on rat pancreatic islets and rat aorta rings. The biological data indicate that most compounds were, like the reference molecule cromakalim, more active on the vascular smooth muscle tissue (myorelaxant effect on 30 mM KCl induced contractions of rat aorta rings) than on the pancreatic tissue (inhibition of 16.7 mM glucose induced insulin release from rat pancreatic islets). However, some drugs (8h, 8i, 9f, 9g, 9h, and 9i) markedly inhibited insulin release and exhibited an activity equivalent or greater than that of diazoxide. Compounds 9h and 9i were also found to be more active on pancreatic β-cells than on vascular smooth muscle cells. Last, the amide 6b was selected in order to examine its mechanism of action on vascular smooth muscle cells. Pharmacological results suggest that the compound acted as a KATP channel opener. In conclusion, the present data indicate that appropriate structural modifications can generate dimethylchromans with pharmacological profiles different from that of cromakalim.